MX2018013222A - Anticuerpos de interferon beta y usos de los mismos. - Google Patents

Anticuerpos de interferon beta y usos de los mismos.

Info

Publication number
MX2018013222A
MX2018013222A MX2018013222A MX2018013222A MX2018013222A MX 2018013222 A MX2018013222 A MX 2018013222A MX 2018013222 A MX2018013222 A MX 2018013222A MX 2018013222 A MX2018013222 A MX 2018013222A MX 2018013222 A MX2018013222 A MX 2018013222A
Authority
MX
Mexico
Prior art keywords
interferon beta
beta antibodies
antibodies
antigen
binding fragments
Prior art date
Application number
MX2018013222A
Other languages
English (en)
Inventor
Roland Lavallie Edward
Mosyak Lidia
M Bennett Eric
V Gulla Stefano
Huard Christine
Elizabeth Buhlmann Janet
Carlos Almagro Juan
R Kodangattil Sreekumar
A Greenberg Steven
Perry HALL James
John Coyle Anthony
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018013222A publication Critical patent/MX2018013222A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invencion se relaciona con anticuerpos, o fragmentos de los mismos de enlace al antigeno, que de manera especifica enlazan el interferon beta (IFNß); dichos anticuerpos, o fragmentos de los mismos de enlace al antigeno, son utiles para varios propositos terapeuticos o de diagnostico.
MX2018013222A 2016-04-29 2017-04-28 Anticuerpos de interferon beta y usos de los mismos. MX2018013222A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662329327P 2016-04-29 2016-04-29
US201662339709P 2016-05-20 2016-05-20
US201762483669P 2017-04-10 2017-04-10
PCT/US2017/030089 WO2017189983A1 (en) 2016-04-29 2017-04-28 Interferon beta antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2018013222A true MX2018013222A (es) 2019-04-22

Family

ID=59215947

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018013222A MX2018013222A (es) 2016-04-29 2017-04-28 Anticuerpos de interferon beta y usos de los mismos.

Country Status (29)

Country Link
US (3) US10829553B2 (es)
EP (2) EP3448419B1 (es)
JP (2) JP6799076B2 (es)
KR (1) KR102527840B1 (es)
CN (1) CN109069606B (es)
AU (1) AU2017258492B2 (es)
BR (1) BR112018072118A2 (es)
CA (1) CA2965652A1 (es)
CO (1) CO2018012497A2 (es)
DK (1) DK3448419T3 (es)
ES (1) ES2950288T3 (es)
FI (1) FI3448419T3 (es)
HR (1) HRP20230605T1 (es)
HU (1) HUE063621T2 (es)
IL (1) IL262244B2 (es)
MX (1) MX2018013222A (es)
MY (1) MY194084A (es)
NZ (1) NZ747225A (es)
PE (1) PE20190371A1 (es)
PH (1) PH12018502275A1 (es)
PL (1) PL3448419T3 (es)
PT (1) PT3448419T (es)
RU (1) RU2750454C2 (es)
SA (1) SA518400327B1 (es)
SG (1) SG11201809456UA (es)
SI (1) SI3448419T1 (es)
TW (1) TWI776808B (es)
WO (1) WO2017189983A1 (es)
ZA (1) ZA201806682B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10829553B2 (en) 2016-04-29 2020-11-10 Pfizer Inc. Interferon beta antibodies and uses thereof
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
EP3784699A4 (en) 2018-04-25 2022-04-13 Prometheus Biosciences, Inc. OPTIMIZED ANTI-TL1A ANTIBODIES
US20220144957A1 (en) * 2019-01-31 2022-05-12 Immunecent Biotechnology, Inc. Novel anti-ifnar1 antibodies
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도
CN114733455B (zh) * 2022-04-15 2023-02-14 北京田园奥瑞生物科技有限公司 一种利用生物改性β-环糊精纳米磁颗粒进行快速哺乳动物***分型的方法
WO2024062420A1 (en) * 2022-09-22 2024-03-28 Pfizer Inc. METHODS OF TREATMENT WITH IFNß ANTIBODIES

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
DE68925365T2 (de) * 1988-10-14 1996-09-12 Berlex Lab PEPTIDE, DIE EPITOPE AUF R-IFN-BETA REPRÄSENTIEREN, ANTIKöRPER DAGEGEN, UND IHRE ANWENDUNG
US6682896B1 (en) * 1988-10-14 2004-01-27 Schering Aktiengesellschaft Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL108584A (en) 1994-02-07 2008-03-20 Yeda Res & Dev Cloning of the interferon-binding protein ALPHA / BETA
ZA9811070B (en) * 1997-12-08 2000-07-03 Genentech Inc Type I interferons.
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US8420353B2 (en) 2002-03-22 2013-04-16 Aprogen, Inc. Humanized antibody and process for preparing same
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
CN102898521A (zh) * 2011-07-26 2013-01-30 上海市免疫学研究所 抗β-干扰素单克隆抗体及其应用
US10647756B2 (en) 2015-05-18 2020-05-12 Pfizer Inc. Humanized antibodies
KR20180020296A (ko) * 2015-06-26 2018-02-27 바이오버라티브 유에스에이 인코포레이티드 자가면역 및 동종면역 장애를 치료하는 방법
US10829553B2 (en) 2016-04-29 2020-11-10 Pfizer Inc. Interferon beta antibodies and uses thereof

Also Published As

Publication number Publication date
KR20190003625A (ko) 2019-01-09
EP4273165A2 (en) 2023-11-08
BR112018072118A2 (pt) 2019-03-19
IL262244A (en) 2018-11-29
EP3448419B1 (en) 2023-06-07
SA518400327B1 (ar) 2022-12-03
PL3448419T3 (pl) 2023-09-04
JP6799076B2 (ja) 2020-12-09
CO2018012497A2 (es) 2018-12-14
JP2021040642A (ja) 2021-03-18
US20170313769A1 (en) 2017-11-02
US20240174742A1 (en) 2024-05-30
ES2950288T3 (es) 2023-10-06
CA2965652A1 (en) 2017-10-29
US20210163588A1 (en) 2021-06-03
AU2017258492B2 (en) 2023-12-07
IL262244B1 (en) 2023-09-01
CN109069606B (zh) 2022-07-01
NZ747225A (en) 2022-07-29
SI3448419T1 (sl) 2023-10-30
EP4273165A3 (en) 2023-12-20
HRP20230605T1 (hr) 2023-09-29
CN109069606A (zh) 2018-12-21
SG11201809456UA (en) 2018-11-29
RU2018141839A3 (es) 2020-10-16
EP3448419A1 (en) 2019-03-06
PE20190371A1 (es) 2019-03-08
TWI776808B (zh) 2022-09-11
WO2017189983A1 (en) 2017-11-02
DK3448419T3 (da) 2023-06-26
RU2018141839A (ru) 2020-05-29
HUE063621T2 (hu) 2024-01-28
US11858986B2 (en) 2024-01-02
PH12018502275A1 (en) 2019-09-09
RU2750454C2 (ru) 2021-06-28
TW201739764A (zh) 2017-11-16
KR102527840B1 (ko) 2023-05-03
MY194084A (en) 2022-11-11
FI3448419T3 (fi) 2023-08-02
IL262244B2 (en) 2024-01-01
ZA201806682B (en) 2022-05-25
JP2019516366A (ja) 2019-06-20
AU2017258492A1 (en) 2018-10-25
US10829553B2 (en) 2020-11-10
JP7102489B2 (ja) 2022-07-19
PT3448419T (pt) 2023-07-26

Similar Documents

Publication Publication Date Title
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12017502180A1 (en) Tau-binding antibodies
MX2018001398A (es) Anticuerpos monoclonales contra bcma.
PH12017500890A1 (en) Antibody drug conjugates
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12017502207A1 (en) Tau-binding antibodies
PH12016501366A1 (en) Novel anti-baff antibodies
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
PH12019502694A1 (en) Anti-trkb antibodies
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
WO2016135462A8 (en) Treatment